ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Preserving limbs and avoiding repeat revascularization in patients with PAD"
Episode Synopsis
In this episode, Dr Sonia Anand and Professor Rupert Bauersachs discuss practical perspectives on how vascular surgeons can improve outcomes in patients with symptomatic PAD undergoing peripheral revascularization.
Further details:
• The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118
• A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext
• A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway inhibition is available here: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048
• The findings from the VOYAGER PAD trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa2000052
• The study investigating the total ischaemic event reduction with rivaroxaban in VOYAGER PAD can be accessed here: https://www.sciencedirect.com/science/article/pii/S0735109721050166
• A meta-analysis of the COMPASS and VOYAGER trials is available here: https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwab128/6360030
• More information on the effect of concomitant clopidogrel on the efficacy and safety of rivaroxaban and aspirin in VOYAGER can be found here: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050465
• The CASPAR paper can be accessed here: https://www.jvascsurg.org/article/S0741-5214(10)00981-X/fulltext
• The Dutch BOA trial paper is available here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07199-8/fulltext
• The summary of product characteristics for rivaroxaban can be found here: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
• The summary of product characteristics for clopidogrel can be found here: https://www.medicines.org.uk/emc/product/5288/smpc
Further details:
• The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118
• A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext
• A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway inhibition is available here: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048
• The findings from the VOYAGER PAD trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa2000052
• The study investigating the total ischaemic event reduction with rivaroxaban in VOYAGER PAD can be accessed here: https://www.sciencedirect.com/science/article/pii/S0735109721050166
• A meta-analysis of the COMPASS and VOYAGER trials is available here: https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwab128/6360030
• More information on the effect of concomitant clopidogrel on the efficacy and safety of rivaroxaban and aspirin in VOYAGER can be found here: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050465
• The CASPAR paper can be accessed here: https://www.jvascsurg.org/article/S0741-5214(10)00981-X/fulltext
• The Dutch BOA trial paper is available here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07199-8/fulltext
• The summary of product characteristics for rivaroxaban can be found here: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
• The summary of product characteristics for clopidogrel can be found here: https://www.medicines.org.uk/emc/product/5288/smpc
In God we trust